Search Results
- Lipitor. Company: Pfizer. Treats: High cholesterol. Lifetime sales: $150.1 billion. No. Last but certainly not least, cholesterol-fighting drug Lipitor has generated a stunning $150.1 billion worth of business for Pfizer as of the end of 2017’s third quarter.
- Humira. Company: AbbVie. Treats: Ankylosing spondylitis, arthritis, Crohn’s disease, plaque psoriasis, ulcerative colitis. Lifetime sales: $109.2 billion.
- Advair. Company: GlaxoSmithKline. Treats: Chronic obstructive pulmonary disease, asthma. Lifetime sales: $95.7 billion. No. Many people may have never even heard of seretide, despite it being the third-best-selling prescription drug on the planet.
- Remicade. Company: Johnson & Johnson. Treats: Rheumatoid arthritis, Crohn’s disease, ulterative colitis. Lifetime sales: $90.3 billion.
Oct 6, 2021 · As our chart shows, the world's best selling prescription drug for HIV treatment, Biktarvy by Gilead Sciences, generated revenues in the U.S. that were five times greater than in the rest of...
- Comirnaty COVID-19 vaccine. Pfizer/BioNTech. $55,918,791,640. The COVID-19 vaccine topped the list of 2022’s 50 best-selling pharmaceuticals. It sold slightly more last year.
- Humira (adalimumab) AbbVie. $21,237,000,000. rheumatoid and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis.
- Keytruda (pembrolizumab) Merck. $20,937,000,000. various cancers.
- Paxlovid. Pfizer. $18,933,000,000. prevention of severe COVID-19.
Mar 13, 2017 · Utilizing the lifetime sales of over one-dozen top-selling branded drugs provided by Forbes between 1996 and 2012 and company reported sales data between 2013 and 2016, here are the 19 best...
- Xarelto (Rivaroxaban) – $6.5bn
- Opdivo (nivolumab) – $6.7bn
- Eylea (aflibercept) – $6.7bn
- Avastin (Bevacizumab) – $6.9bn
- Herceptin (trastuzumab) – $7bn
- Enbrel (Etanercept) – $7.1bn
- Keytruda (pembrolizumab) – $7.1bn
- Revlimid (Lenalidomide) – $9.7bn
- Eliquis (apixaban) – $9.8bn
- Humira (adalimumab) – $19.9Bn
Developed by Johnson & Johnson (J&J) and Bayer, Xarelto recorded a worldwide sales growth of 5% in 2018 compared to 2017. It is the only oral coagulant approved in both the US and Europe to treat coronary artery disease (CAD) and peripheral artery disease. Xarelto has remained Bayer’s best-selling product in the pharmaceuticals segment in 2018 driv...
Opdivo is the world’s first-approved anti-programmed death receptor (PD-1) developed by Bristol Myers Squibb(BMS). Sales of Opdivo rose by 36% worldwide in 2018 and by 37% in the US. The immunotherapy drug was first approved in Japan and then in the US in 2014. Currently, Opdivo is approved for the treatment of 12 types of cancer either as monother...
Eylea is approved for the treatment of wet macular degeneration in the US, Europe, and Australia. In Japan, the drug is approved for the treatment of macular oedema secondary to retinal vein occlusion. The increase in sales of the drug outside the US boosted the global sales of the drug by 12% in 2018 compared to 2017. First launched in 2011, Eylea...
Developed by Roche, Avastin’s net sales grew by 3% worldwide supported by a 12% growth in the international market especially due to broader market penetration in China The increased demand for ovarian cancer treatment in Japan resulted in a 3% growth in sales in Japan, while the European sales declined by 1% due to a reduction in the reimbursement...
Biosimilars competition negatively impacted the sales of Roche’s Herceptin in Europe and Japan as a 16% sales decline was observed in both regions. Price cuts by the government in Japan also added to the decline. First approved in 1998 as the first drug to treat HER2-positive breast cancer, Herceptin is also currently approved for the treatment of ...
Amgen’s Enbrel reported consolidated net sales of $5bn in the US and Canada, while Pfizerreported $2.1bn sales in the Rest-of-the-World (RoW) region. In Japan, Pfizer markets Enbrel in partnership with the Japanese pharmaceutical company Takeda. The drug is facing increasing biosimilar competition in the European markets, which is negatively impact...
Net sales of Merck’s Keytruda grew by approximately 47% in 2018 owing to approval in multiple indications. The drug is approved for the treatment of 11 types of cancer, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma and cervical cancer either as a monotherapy in combination with other therapies. Keytruda was t...
In 2018, Celgene’s Revlimid recorded approximately an 18% year-over-year growth in net sales driven by increased treatment duration and market share. Investments in research and development for label expansion either as monotherapy or in combination have helped the company in maintaining its revenues. Initially approved in 2005, the drug is indicat...
Eliquis is one of the strong and growing franchises of BMS with a 32% growth in net sales in 2018. It was jointly developed and commercialised by BMS and Pfizer, with the latter contributing 50% to 60% of the development cost of the drug. Pfizer reported a 36% growth in the net sales of the drug worldwide. Initially launched in 2012, the drug is a ...
Humira is Abbvie’s single largest product and its net sales grew by 7% worldwide in 2018, despite the launch of biosimilars in various parts of the world. The drug accounted for approximately 61% of the total net revenues of the company in 2018. The growth is primarily attributed to an increase in the market across different therapeutic indications...
Aug 22, 2022 · Listen to the article 9 min. The top pharma companies in the world all have their bestselling drugs, which are blockbusters that form the base of their revenue. Halfway through the year, many of those treatments are already on their way to surpassing last year’s numbers.
Dec 8, 2022 · 50 most prescribed drugs of 2022. The following are the most popular drugs based on the most filled scripts through SingleCare from Jan. 1, 2022 through Oct. 31, 2022, excluding opioids and weight-loss drugs. Vitamin D (Drisdol, Calciferol) Amoxicillin (Amoxil, Biomox, Polymox) Levothyroxine (Synthroid, Euthyrox, Levoxyl, Unithroid)